Peer-influenced content. Sources you trust. No registration required. This is HCN.
Clinical Advances in Hematology & Oncology
The bispecific antibody targets both CD20 and CD3 proteins and has demonstrated the capacity of activated immune cells to eliminate lymphoma cells, achieving deep and potentially curable remissions.
Hematology/Oncology November 13th 2023
OBR Oncology
This recent study suggests that systemic treatment with chemotherapy plus immunotherapy may allow patients with muscle-invasive bladder cancer (MIBC) to avoid radical cystectomy.
Oncology, Medical October 23rd 2023
The New England Journal of Medicine
This phase 2 trial demonstrated that tarlatamab showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell lung cancer. With a manageable safety profile and no new safety signals identified, tarlatamab could represent a significant advancement in the treatment landscape for these patients.
Hematology Advisor
Discover how CRISPR-engineered CD45 CAR T-cells could alter the treatment landscape for various blood cancers, offering a more versatile and less risky approach.
Hematology October 9th 2023
Discover how base editing via CRISPR-guided cytidine deamination could revolutionize CAR T-cell therapy for T-cell cancers, offering a promising approach to treating relapsed or refractory cases in pediatric patients.
Hematology/Oncology September 11th 2023
Explore the nuanced implications of the FDA’s accelerated approval of enfortumab vedotin plus pembrolizumab for cisplatin-ineligible urothelial carcinoma patients, including questions on optimal treatment duration and adverse effects.
Oncology, Medical August 28th 2023